HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Are regimens containing rituximab effective in the initial treatment of Epstein-Barr virus-positive natural killer cell lymphoproliferative disease-associated hemophagocytic lymphohistiocytosis?

AuthorsShinsaku Imashuku, Naoko Kudo, Kagekatsu Kubo, Akihiro Yachie
JournalInternational journal of hematology (Int J Hematol) Vol. 98 Issue 3 Pg. 375-7 (Sep 2013) ISSN: 1865-3774 [Electronic] Japan
PMID23975519 (Publication Type: Case Reports, Letter)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Immunosuppressive Agents
  • Rituximab
  • Etoposide
  • Cyclosporine
  • Prednisolone
Topics
  • Antibodies, Monoclonal, Murine-Derived (administration & dosage)
  • Cyclosporine (administration & dosage)
  • Drug Therapy, Combination
  • Etoposide (administration & dosage)
  • Humans
  • Immunologic Factors (administration & dosage)
  • Immunosuppressive Agents (administration & dosage)
  • Killer Cells, Natural (pathology, virology)
  • Lymphohistiocytosis, Hemophagocytic (complications, diagnosis, drug therapy)
  • Lymphoproliferative Disorders (complications, diagnosis, drug therapy, pathology)
  • Male
  • Middle Aged
  • Prednisolone (administration & dosage)
  • Rituximab
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: